Science Current Events | Science News | Brightsurf.com
 

Automated design for drug discovery

December 13, 2012
A system of 'automated design' for new drugs could help develop the complex therapies needed for many medical conditions while also improving drug safety and efficiency, new research from the University of Dundee has shown.

The 'Moneyball' approach taken by the research team utilises the principles of advanced statistical and data analysis which have seen to be increasingly influential in areas as varied as sport, finance and in forecasting the recent US Presidential election.

As more complex drugs are needed to treat more complicated problems - particularly in areas such as neuroscience, infectious diseases and cancer - the task facing biologists and chemists is daunting. However, researchers at the College of Life Sciences at Dundee, in collaboration with partners in North America, have shown that an automated computational process analysing huge amounts of existing data could provide a valuable new tool in drug discovery.

The innovative approach taken by the research team mimics the creative process of human chemists, where drug molecules are steadily improved through successive cycles of design and selection.

"One of the things that makes drug discovery so hard is that you're trying to improve several different properties at the same time," said Professor Andrew Hopkins, Chair of Medicinal Informatics at Dundee. "Evolution is a mechanism than can be applied to solving these kinds of optimisation problems, and the iterative process of adaption and selection of hundreds of thousand of possible solutions can be simulated in a computer.

"We have effectively proved the concept of automated design of new compounds, showing that by using algorithms to process massive amounts of data we can tackle problems of huge complexity. The system solves the design problem by using computational evolution to mimic the design process of human chemists but running it on a very large scale."

The research is published in the journal Nature. The research team's work is funded by the Biotechnology and Biological Sciences Research Council.

Drugs have to be able to deliver their primary effects and not present adverse side effects or toxicity that render them unsafe. But for complex conditions drugs also have to be designed to hit multiple targets. Designing drugs to this kind of multi-target profile is a complex and exceedingly difficult task for medicinal chemistry.

Professor Hopkins and colleagues developed an automated adaptive design approach that can mimic the creative, iterative process of medicinal chemists by using computational evolution of large numbers of compounds. They initially used it to look at an existing drug, Donepezil, which is used in treating Alzheimer's Disease.

"Professor Sir James Black, the Nobel Laureate and former Chancellor of the University, proposed that 'the most fruitful basis for the discovery of a new drug is to start with an old drug' and we followed that advice," said Professor Hopkins.

"We took the structure of Donepezil as a starting point and from there the system evolved its structure, computationally, over many generations to a variety of different profiles across a range of drug targets. The predicted profiles were then tested experimentally and we found that 75% of them were confirmed to be correct.

"This proof of concept shows that we could make significant advances in discovering and designing complex drugs, which could lead to improvements in safety and efficacy, while also potentially reducing the cost of drug discovery, which is a high-risk and expensive process."

Professor Hopkins said improvements in data capture and management were key to developing the research.

"Just a few years ago this would not have been possible because we need the existing drug data to build on and it was not held in a way that it could be analysed like this. But there have been significant developments, aided by groups like ChEMBL in Cambridge, who are funded by The Wellcome Trust, in making drug design data available in a format computers can process. What we have found particularly exciting is the way the algorithm has been able to learn from the human experience of drug design and mimic it on a massive scale to solve complex design problems."

This phenomenon is reflected in the name of a new spin out company which has been formed to commercialise the technology - ex scientia - which is the Latin for "from knowledge".

University of Dundee


Related Drug Discovery Current Events and Drug Discovery News Articles


Stanford researchers compare mammals' genomes to aid human clinical research
For years, scientists have considered the laboratory mouse one of the best models for researching disease in humans because of the genetic similarity between the two mammals.

Computer model sets new precedent in drug discovery
A major challenge faced by the pharmaceutical industry has been how to rationally design and select protein molecules to create effective biologic drug therapies while reducing unintended side effects - a challenge that has largely been addressed through costly guess-and-check experiments.

Establishment of induced pluripotent stem cells from Werner syndrome fibroblasts
Werner syndrome is characterized by the premature appearance of features associated with normal aging and cancer predisposition. This syndrome occurs frequently in Japan, affecting 1 in 20,000 to 1 in 40,000 people.

IU-led research team identifies genetic variant linked to better memory performance
People with a newly identified genetic variant perform better on certain types of memory tests, a discovery that may point the way to new treatments for the memory impairments caused by Alzheimer's disease or other age-associated conditions.

Brain protein influences how the brain manages stress; suggests new model of depression
The brain's ability to effectively deal with stress or to lack that ability and be more susceptible to depression, depends on a single protein type in each person's brain.

Scientists unveil new targets, test to develop treatments for memory disorder
In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute (TSRI) have identified a number of new therapeutic targets for memory disorders and have developed a new screening test to uncover compounds that may one day work against those disorders.

Catalyst-where-you-want-it method expands the possibilities for new drug development
Chemists at The Scripps Research Institute (TSRI) and the Shanghai Institute of Organic Chemistry have described a method for creating and modifying organic compounds that overcomes a major limitation of previous methods.

'Rewriting' the way to make natural drug compounds
One of the big hurdles in bringing drugs to market is the difficulty of producing large enough quantities of potential compounds to conduct clinical trials.

New test shows promise in identifying new drugs to treat Lyme disease
Researchers from the Johns Hopkins Bloomberg School of Public Health have developed a test they say will allow them to test thousands of FDA-approved drugs to see if they will work against the bacteria that causes tick-borne Lyme disease.

New research offers hope in treating sleeping sickness
In early drug dis≠covery, you need a starting point, says North≠eastern Uni≠ver≠sity asso≠ciate pro≠fessor of chem≠istry and chem≠ical biology Michael Pollastri.
More Drug Discovery Current Events and Drug Discovery News Articles

Drug Discovery and Development: Technology in Transition, 2e

Drug Discovery and Development: Technology in Transition, 2e
by Raymond G Hill (Author)


The modern pharmacopeia has enormous power to alleviate disease, and owes its existence almost entirely to the work of the pharmaceutical industry. This book provides an introduction to the way the industry goes about the discovery and development of new drugs. The first part gives a brief historical account from its origins in the mediaeval apothecaries' trade, and discusses the changing understanding of what we mean by disease, and what therapy aims to achieve, as well as summarising case histories of the discovery and development of some important drugs. The second part focuses on the science and technology involved in the discovery process: the stages by which a promising new chemical entity is identified, from the starting point of a medical need and an idea for addressing it. A...

Drug Discovery: Practices, Processes, and Perspectives

Drug Discovery: Practices, Processes, and Perspectives
by Jie Jack Li (Editor), E. J. Corey (Editor)


Edited by two distinguished chemists from academia and industry, this book presents an up-to-date overview of major aspects of drug discovery. It covers all ends of the discovery process from target selection to major therapeutic areas. Encompassing historical information, current methods, and future prospects, the coverage addresses novice medicinal chemists, providing them with a jump-start to their understanding of drug discovery. The perspectives on drug discovery, authored by experts in different fields and using case studies, also offer benefits to veteran medicinal and process chemists.

Hallelujah Moments: Tales of Drug Discovery

Hallelujah Moments: Tales of Drug Discovery
by Eugene H. Cordes (Author)


Drug discovery in the pharmaceutical industry has important consequences for the health and wellbeing of people everywhere. However, the general public knows little about the paths through which basic research findings are translated into products that protect or restore human health: the route from the laboratory bench to the bedside. In Hallelujah Moments, Eugene Cordes reveals how some of the most important and influential drugs have been brought into the practice of clinical medicine through the wit and determination of scientists in academia and industry. He shares his firsthand knowledge of the drug-discovery world, having spent a long and distinguished career in both the academic and industrial settings. These tales are "adventure stories," and they trace the route of important...

Real World Drug Discovery: A Chemist's Guide to Biotech and Pharmaceutical Research

Real World Drug Discovery: A Chemist's Guide to Biotech and Pharmaceutical Research
by Robert M. Rydzewski (Author)


Drug discovery increasingly requires a common understanding by researchers of the many and diverse factors that go into the making of new medicines. The scientist entering the field will immediately face important issues for which his education may not have prepared him: project teams, patent law, consultants, target product profiles, industry trends, Gantt charts, target validation, pharmacokinetics, proteomics, phenotype assays, biomarkers, and many other unfamiliar topics for which a basic understanding must somehow be obtained. Even the more experienced scientist can find it frustratingly difficult to get an overview of the many factors involved in modern drug discovery and often only after years of exploring does a whole and integrated picture emerge in the mind of the researcher....

The Future of Drug Discovery: Who Decides Which Diseases to Treat?

The Future of Drug Discovery: Who Decides Which Diseases to Treat?
by Tamas Bartfai (Author), Graham V. Lees (Author)


The Future of Drug Discovery: Who decides which diseases to treat? provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. The authors posit that as a result of increasing risk aversion and accelerated savings in research and development, the industry is not developing drugs for increasingly prevalent diseases, such as Alzheimer's disease, untreatable pain, antibiotics and more. This book carefully exposes the gap between the medicines and therapies we need and the current business path. By analyzing the situation and discussing prospects for the next decade, the The Future of Drug Discovery is a timely book for all those who care about the development needs for drugs for disease.This thought-provoking...

Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships (Wiley Series on Technologies for the Pharmaceutical Industry)

Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships (Wiley Series on Technologies for the Pharmaceutical Industry)
by Rathnam Chaguturu (Editor), Ferid Murad (Editor)


Can academia save the pharmaceutical industry?The pharmaceutical industry is at a crossroads. The urgent need for novel therapies cannot stem the skyrocketing costs and plummeting productivity plaguing R&D, and many key products are facing patent expiration. Dr. Rathnam Chaguturu presents a case for collaboration between the pharmaceutical industry and academia that could reverse the industry's decline. Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships provides insight into the potential synergy of basing R&D in academia while leaving drug companies to turn hits into marketable products. As Founder and CEO of iDDPartners, focused on pharmaceutical innovation, Founding president of the International Chemical Biology Society, and Senior...

Drugs: From Discovery to Approval

Drugs: From Discovery to Approval
by Rick Ng (Author)


"Concise and easy to read, the book quickly introduces basic concepts, then moves on to discuss target selection and the drug discovery process for both small and large molecular drugs." - Doody's Reviews , May 2009 "The second edition of a book that offers a user-friendly step-by-step introduction to all the key processes involved in bringing a drug to the market, including the performance of preclinical trials." - Chemistry World , February 2009 The new edition of this best-selling book continues to offer a user-friendly, step-by-step introduction to all the key processes involved in bringing a drug to the market, including the performance of pre-clinical studies, the conduct of human clinical trials, regulatory controls, and even the manufacturing processes for pharmaceutical...

Drug Discovery: From Bedside to Wall Street

Drug Discovery: From Bedside to Wall Street
by Tamas Bartfai (Author), Graham V. Lees (Author)


Everyone expects something from the drug industry. Physicians and patients, investors, regulators and administrators all have an active interest. Everyone wants to know what makes drugs 'work' medically and economically. Why are drugs so expensive? Is it the drug companies or investors who demand high profits? What governs the pharmacoeconomics? Why are so few diseases treatable?

This book opens the windows and doors of the industry telling the story of drug development by using real stories from inside the process.

* Co-written by Graham Lees and Tamas Bartfai who has been involved in the development of drugs taken by more that 20 million people every day
* Opens the windows and doors of the most regulated industry in the world,...

Protein-Protein Interactions in Drug Discovery, Volume 56

Protein-Protein Interactions in Drug Discovery, Volume 56
by Alexander Dömling (Editor), Raimund Mannhold (Editor), Hugo Kubinyi (Editor), Gerd Folkers (Editor)


Treating protein-protein interactions as a novel and highly promising class of drug targets, this volume introduces the underlying strategies step by step, from the biology of PPIs to biophysical and computational methods for their investigation. The main part of the book describes examples of protein targets for which small molecule modulators have been developed, covering such diverse fields as cancer, autoimmune disorders and infectious diseases. Tailor-made for the practicing medicinal chemist, this ready reference includes a wide selection of case studies taken straight from the development pipeline of major pharmaceutical companies to illustrate the power and potential of this approach.

Translational Medicine and Drug Discovery

Translational Medicine and Drug Discovery
by Bruce H. Littman MD (Editor), Rajesh Krishna PhD FCP (Editor)


This book, edited by two innovative leaders in the field, focuses on the new discipline of translational medicine as it pertains to drug development within the pharmaceutical and biotechnology industry. Translational medicine seeks to translate biological and molecular knowledge of disease and how drugs work into innovative development strategies that reduce the cost and increase the speed of delivering new medicines for patients. This book outlines general strategies, biomarker development, imaging tools, translational human models, and examples of their application to real drug development. The latest thinking is presented by researchers from many of the world's leading drug development companies, including Pfizer, Merck, Eli Lilly, Abbott, and Novartis, as well as academic institutions...

© 2014 BrightSurf.com